{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T22:21:16Z","timestamp":1791584476133,"version":"4.3.4"},"reference-count":107,"publisher":"Informa UK Limited","issue":"2","license":[{"start":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T00:00:00Z","timestamp":1770422400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T00:00:00Z","timestamp":1770422400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"funder":[{"DOI":"10.13039\/100000104","name":"National Aeronautics and Space Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000104","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Toxicology"],"published-print":{"date-parts":[[2026,2,7]]},"DOI":"10.1080\/10408444.2025.2533943","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T07:41:36Z","timestamp":1775720496000},"page":"93-126","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["A framework for assessing the safety of degraded pharmaceuticals for long-duration space missions - Part 1: framework development"],"prefix":"10.1080","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1326-5580","authenticated-orcid":false,"given":"Andrey","family":"Massarsky","sequence":"first","affiliation":[{"name":"Stantec","place":["Irvine, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4821-9477","authenticated-orcid":false,"given":"Veneese J. B.","family":"Evans","sequence":"additional","affiliation":[{"name":"Stantec","place":["Irvine, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9993-9549","authenticated-orcid":false,"given":"Ernest S.","family":"Fung","sequence":"additional","affiliation":[{"name":"Stantec","place":["Irvine, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8288-5345","authenticated-orcid":false,"given":"Lisa G. L.","family":"Yang","sequence":"additional","affiliation":[{"name":"Stantec","place":["San Francisco, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6069-0689","authenticated-orcid":false,"given":"Keegan L.","family":"Rogers","sequence":"additional","affiliation":[{"name":"Stantec","place":["Denver, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9280-4177","authenticated-orcid":false,"given":"Amanda N.","family":"Buerger","sequence":"additional","affiliation":[{"name":"Stantec","place":["Cincinnati, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3431-9645","authenticated-orcid":false,"given":"Andrew","family":"Maier","sequence":"additional","affiliation":[{"name":"Stantec","place":["Cincinnati, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9886-1623","authenticated-orcid":false,"given":"John F.","family":"Reichard","sequence":"additional","affiliation":[{"name":"NASA Johnson Space Center","place":["Houston, USA"]},{"name":"Department of Environmental and Public Health Sciences, University of Cincinnati","place":["Cincinnati, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,4,9]]},"reference":[{"issue":"2","key":"e_1_3_3_2_1","first-page":"137","article-title":"ESR Studies on characteristic physio-chemical effects of some irradiated antibiotics","volume":"31","author":"Abdou S","year":"2018","unstructured":"Abdou S, Ebraheem S. 2018. ESR Studies on characteristic physio-chemical effects of some irradiated antibiotics. Egypt J Radiat Sci Appl. 31(2):137\u2013142.","journal-title":"Egypt J Radiat Sci Appl"},{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2023.105355"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1773-2247(07)50038-9"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2016.02.004"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1201\/9780849359194"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/0378-5173(96)04597-8"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-0716-1960-5"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2020.104843"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.23228"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2014.01.004"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1080\/10408440701749421"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2021.06.012"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2012.4501"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsomega.2c05693"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2011.03.030"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.3390\/toxics13040243"},{"key":"e_1_3_3_18_1","unstructured":"CompTox Chemicals Dashboard. 2024. CompTox Chemicals Dashboard v2.4.1. Available from: https:\/\/comptox.\u200cepa.gov\/dashboard\/."},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1089\/bsp.2009.0011"},{"key":"e_1_3_3_20_1","first-page":"18062","volume-title":"Radiation impact on pharmaceutical stability: retrospective data review","author":"Daniels VR","year":"2018","unstructured":"Daniels VR, Bayuse TM, Mcguire RKM, Antonsen EL, Putcha L. 2018. Radiation impact on pharmaceutical stability: retrospective data review [#18062]. Presented at NASA Human Research Program Investigators\u2019 Workshop: the Gateway to Mars. 2018."},{"key":"e_1_3_3_21_1","first-page":"171","article-title":"Radiation sterilization of ephedrine in the solid state","volume":"53","author":"Dettlaff K","year":"2008","unstructured":"Dettlaff K, T\u0119\u017cyk A, Marciniec B, Wachowiak R, Naskrent M, Bednarek B. 2008. Radiation sterilization of ephedrine in the solid state. Chem Anal (Warsaw). 53:171\u2013186.","journal-title":"Chem Anal (Warsaw)"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-011-9270-0"},{"key":"e_1_3_3_23_1","unstructured":"[EMA] European Medicines Agency. Nitrosamine impurities in human medicinal products. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/opinion-any-scientific-matter\/nitrosamines-emea-h-a53-1490-assessment-report_en.pdf."},{"key":"e_1_3_3_24_1","unstructured":"[EPA IRIS] Environmental Protection Agency Integrated Risk Information System. 2024. Integrated Risk Information System. Available from: https:\/\/www.epa.gov\/iris."},{"key":"e_1_3_3_25_1","unstructured":"[EPA] Environmental Protection Agency. 2009. Risk assessment guidance for superfund volume I: human health evaluation manual (part F supplemental guidance for inhalation risk assessment). Available from: https:\/\/www.epa.gov\/sites\/default\/files\/2015-09\/documents\/partf_200901_final.pdf."},{"key":"e_1_3_3_26_1","unstructured":"EUR-Lex. 2017. Commission Regulation (EU) 2017\/706 of 19 April 2017 amending Annex VII to Regulation (EC) No 1907\/2006 of the European Parliament and of the Council on the Registration Evaluation Authorisation and Restriction of Chemicals (REACH) as regards skin sensitisation and repealing Commission Regulation (EU) 2016\/1688 Europa."},{"key":"e_1_3_3_27_1","unstructured":"[FDA] Food and Drug Administration. 2003. Guidance for industry Q1A(R2) stability testing of new drug substances and products. Available from: https:\/\/www.fda.gov\/media\/71707\/download."},{"key":"e_1_3_3_28_1","unstructured":"[FDA] Food and Drug Administration. 2004. Guidance for industry Q1E evaluation of stability data. Available from: https:\/\/www.fda.gov\/media\/71722\/download."},{"key":"e_1_3_3_29_1","unstructured":"[FDA] Food and Drug Administration. 2006. Guidance for industry Q3B(R2) impurities in new drug products. Available from: https:\/\/www.iarc.who.int\/."},{"key":"e_1_3_3_30_1","unstructured":"[FDA] Food and Drug Administration. 2021. Control of nitrosamine impurities in human drugs. Guidance for industry. Available from: https:\/\/www.fda.gov\/media\/141720\/download."},{"key":"e_1_3_3_31_1","unstructured":"[FDA] Food and Drug Administration. 2022. Good ANDA submission practices. Guidance for industry. Available from: https:\/\/www.fda.gov\/\u200cmedia\/110689\/download."},{"key":"e_1_3_3_32_1","unstructured":"[FDA] Food and Drug Administration. 2023. Guidance for industry M7(R2) assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-m7r2-assessment-and-control-dna-reactive-mutagenic-impurities-pharmaceuticals."},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2022.105159"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.14573\/altex.1911261"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.3389\/ftox.2024.1331803"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00204-020-02862-8"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2024.105645"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.3329\/bjm.v23i2.886"},{"key":"e_1_3_3_39_1","unstructured":"[IARC] International Agency for Research on Cancer. 2024. International Agency for Research on Cancer. Available from: https:\/\/www.iarc.who.int\/."},{"key":"e_1_3_3_40_1","unstructured":"[ICH] International Council for Harmonisation. 2017. ICH harmonised guideline: assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk M7(R1) Step 4 version International Council for Harmonisation."},{"key":"e_1_3_3_41_1","unstructured":"[ICH] International Council for Harmonisation. 2023. ICH harmonised guideline: assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk M7 (R2): final version International Council for Harmonisation."},{"key":"e_1_3_3_42_1","first-page":"56","volume-title":"The interdepartmental group on health risks from chemicals","author":"[IGHRC] Interdepartmental Group on Health Risks from Chemicals","year":"2006","unstructured":"[IGHRC] Interdepartmental Group on Health Risks from Chemicals. 2006. Guidelines on route-to-route extrapolation of toxicity data when assessing health risks of chemicals. In IGHRC (Ed.), The interdepartmental group on health risks from chemicals. Institute of Environment and Health, Cranfield University, UK, Silsoe, p. 56."},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2020.104688"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2024.105644"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4419-0889-6_17"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.23925"},{"key":"e_1_3_3_47_1","volume-title":"Internal report","author":"Khan M","year":"2014","unstructured":"Khan M, Wotring VE. 2014. FDA Comprehensive stability evaluation of three medications. Universities Space Research Association: Houston TX. Internal report."},{"key":"e_1_3_3_48_1","unstructured":"Kim MHY Plante I. 2015. An assessment of how radiation incurred during a Mars mission could affect food and pharmaceuticals."},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.1021\/mp5003976"},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.1080\/10408444.2018.1429386"},{"key":"e_1_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.34172\/apb.2022.010"},{"key":"e_1_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.1006\/rtph.1996.1076"},{"key":"e_1_3_3_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.fct.2003.08.006"},{"key":"e_1_3_3_54_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12010010"},{"key":"e_1_3_3_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2011.09.004"},{"key":"e_1_3_3_56_1","unstructured":"Lhasa. 2024. Our solutions. Available from: https:\/\/www.lhasalimited.org\/solutions\/."},{"key":"e_1_3_3_57_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.20636"},{"key":"e_1_3_3_58_1","doi-asserted-by":"publisher","DOI":"10.1289\/EHP8495"},{"key":"e_1_3_3_59_1","doi-asserted-by":"publisher","DOI":"10.1023\/B:JTAN.0000033215.77806.b0"},{"key":"e_1_3_3_60_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1025465726691"},{"key":"e_1_3_3_61_1","doi-asserted-by":"publisher","DOI":"10.1080\/10408444.2026.2633422"},{"key":"e_1_3_3_62_1","volume-title":"Derivation and validation of parenteral classification strategy","author":"McGovern T.","year":"2018","unstructured":"McGovern T. 2018. Derivation and validation of parenteral classification strategy. PQRI PODP Extractables & Leachables Workshop: Rockville, MD."},{"key":"e_1_3_3_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2016.12.040"},{"key":"e_1_3_3_64_1","volume-title":"Nonclinical review of extractable leachable studies: Practical advice from an FDA reviewer","author":"Mellon D.","year":"2019","unstructured":"Mellon D. 2019. Nonclinical review of extractable leachable studies: Practical advice from an FDA reviewer. Extractables & Leachables USA: Arlington, VA."},{"key":"e_1_3_3_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2021.104895"},{"key":"e_1_3_3_66_1","doi-asserted-by":"publisher","DOI":"10.1177\/07482337231209091"},{"key":"e_1_3_3_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0278-6915(96)00049-x"},{"key":"e_1_3_3_68_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-012-0782-9"},{"key":"e_1_3_3_69_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241411488"},{"key":"e_1_3_3_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jece.2016.04.034"},{"key":"e_1_3_3_71_1","volume-title":"Space radiation and astronaut health: managing and communicating cancer risks","author":"[NAS] National Academies of Sciences","year":"2021","unstructured":"[NAS] National Academies of Sciences. 2021. Space radiation and astronaut health: managing and communicating cancer risks. Washington, DC, The National Academies Press."},{"key":"e_1_3_3_72_1","author":"[NASA] National Aeronautics and Space Administration","year":"2019","unstructured":"[NASA] National Aeronautics and Space Administration. 2019. International Environmental Control and Life Support System Interoperability Standards: baseline, Multilateral Coordination Board, National Aeronautics and Space Administration.","journal-title":"International Environmental Control and Life Support System Interoperability Standards: baseline, Multilateral Coordination Board, National Aeronautics and Space Administration"},{"key":"e_1_3_3_73_1","unstructured":"[NASA] National Aeronautics and Space Administration. 2023. Evidence report: risk of ineffective or toxic medication during long-duration exploration spaceflight. Available from https:\/\/humanresearchroadmap.nasa.gov\/Evidence\/other\/Pharm%20evidence%20report_12-20-23_FINAL.pdf."},{"key":"e_1_3_3_74_1","unstructured":"[NASA] National Aeronautics and Space Administration. 2024a. Introduction to the IMPACT probabilistic risk and tradespace analysis tool for medical system design. Available from: https:\/\/ntrs.nasa.gov\/citations\/20220015765."},{"key":"e_1_3_3_75_1","unstructured":"[NASA] National Aeronautics and Space Administration. 2024b. Risk of ineffective or toxic medications during long-duration exploration spaceflight. Available from: https:\/\/humanresearchroadmap.nasa.gov\/Risks\/risk.aspx?i=177."},{"key":"e_1_3_3_76_1","volume-title":"Committee on the institutional means for assessment of risks to public health. Risk assessment in the federal government: managing the process","author":"[NRC] National Research Council (US)","year":"1983","unstructured":"[NRC] National Research Council (US). 1983. Committee on the institutional means for assessment of risks to public health. Risk assessment in the federal government: managing the process. Washington (DC): national Academies Press (US). Available from: https:\/\/nap.nationalacademies.org\/catalog\/366\/risk-assessment-in-the-federal-government-managing-the-process."},{"key":"e_1_3_3_77_1","unstructured":"[NTP] National Toxicology Program. 2024. National Toxicology Program. Available from: https:\/\/ntp.niehs.nih.gov\/."},{"key":"e_1_3_3_78_1","unstructured":"[OECD] Organisation for Economic Co-operation and Development. 2014. The adverse outcome pathway for skin sensitisation initiated by covalent binding to proteins. OECD Publishing; Paris France: 2014. (OECD Series on Testing and Assessment No. 168)."},{"key":"e_1_3_3_79_1","unstructured":"[OECD] Organisation for Economic Co-operation and Development. 2021. Guideline No. 497: guideline on defined approaches for skin sensitisation Organization for Economic Cooperation and Development."},{"key":"e_1_3_3_80_1","unstructured":"[OECD] Organisation for Economic Co-operation and Development. 2024. The OECD QSAR Toolbox. Available from: https:\/\/www.oecd.org\/chemicalsafety\/risk-assessment\/oecd-qsar-toolbox.htm."},{"key":"e_1_3_3_81_1","unstructured":"[PQRI] Product Quality Research Institute. 2021. Safety thresholds and best demonstrated practices for extractables and leachables in parenteral drug products (intravenous subcutaneous and intramuscular). Available from: https:\/\/pqri.org\/wp-content\/uploads\/2022\/03\/PQRI-PDP-Recommendation-2022.pdf."},{"key":"e_1_3_3_82_1","doi-asserted-by":"publisher","DOI":"10.1021\/mp400083h"},{"key":"e_1_3_3_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2025.105776"},{"key":"e_1_3_3_84_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-05526-4"},{"key":"e_1_3_3_85_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2016.00117"},{"key":"e_1_3_3_86_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00204-021-03034-y"},{"key":"e_1_3_3_87_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41526-023-00271-6"},{"key":"e_1_3_3_88_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.crtox.2024.100205"},{"key":"e_1_3_3_89_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2015.05.016"},{"key":"e_1_3_3_90_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2024.105647"},{"issue":"7622","key":"e_1_3_3_91_1","first-page":"416","article-title":"Understanding the chemical basis of drug stability and degradation","volume":"285","author":"Snape T","year":"2010","unstructured":"Snape T, Astles A, Davies J. 2010. Understanding the chemical basis of drug stability and degradation. Pharm J. 285(7622):416\u2013417.","journal-title":"Pharm J"},{"key":"e_1_3_3_92_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jcim.2c01422"},{"key":"e_1_3_3_93_1","doi-asserted-by":"publisher","DOI":"10.1039\/c9cc06429j"},{"key":"e_1_3_3_94_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2015.05.024"},{"key":"e_1_3_3_95_1","unstructured":"STopTox. 2024. STopTox. Available from: https:\/\/stoptox.mml.unc.edu\/."},{"key":"e_1_3_3_96_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.radphyschem.2019.01.025"},{"key":"e_1_3_3_97_1","article-title":"Effect of sterilization on drugs and lenses for ophthalmic applications","author":"Topete A","year":"2016","unstructured":"Topete A, Oliveira A, Galante R, Bozukova D, Saramago B, Ana S. 2016. Effect of sterilization on drugs and lenses for ophthalmic applications. Front Bioeng Biotechnol. Conference Abstract: 10th. World Biomaterials Congress.","journal-title":"Front Bioeng Biotechnol. Conference Abstract: 10th. World Biomaterials Congress"},{"key":"e_1_3_3_98_1","unstructured":"[USDHHS] United States Department of Health and Human Services. 2023. Recommended acceptable intake limits for nitrosamine drug substance-related impurities (NDSRIs): guidance for industry U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER)."},{"key":"e_1_3_3_99_1","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.3.3.15608"},{"key":"e_1_3_3_100_1","doi-asserted-by":"publisher","DOI":"10.1081\/pdt-120003494"},{"key":"e_1_3_3_101_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-6395(03)80006-5"},{"key":"e_1_3_3_102_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2019.104524"},{"key":"e_1_3_3_103_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2025.105861"},{"key":"e_1_3_3_104_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsps.2022.12.010"},{"key":"e_1_3_3_105_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-015-9834-5"},{"issue":"6","key":"e_1_3_3_106_1","first-page":"1253","article-title":"The radiolytic studies of ceftriaxone in the solid state","volume":"72","author":"Zalewski P","year":"2015","unstructured":"Zalewski P, Szymanowska-Powa\u0142wska D, Garbacki P, Paczkowska-Walendowska M, Ciomek A, Cielecka-Piontek J. 2015. The radiolytic studies of ceftriaxone in the solid state. Acta Poloniae Pharmaceutica\u2013Drug Research. 72(6):1253\u20131258.","journal-title":"Acta Poloniae Pharmaceutica\u2013Drug Research"},{"key":"e_1_3_3_107_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1750-3841.2009.01265.x"},{"key":"e_1_3_3_108_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.comtox.2022.100237"}],"container-title":["Critical Reviews in Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10408444.2025.2533943","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/10408444.2025.2533943","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10408444.2025.2533943","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T18:02:52Z","timestamp":1790964172000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/10408444.2025.2533943"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,7]]},"references-count":107,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2,7]]}},"alternative-id":["10.1080\/10408444.2025.2533943"],"URL":"https:\/\/doi.org\/10.1080\/10408444.2025.2533943","relation":{},"ISSN":["1040-8444","1547-6898"],"issn-type":[{"value":"1040-8444","type":"print"},{"value":"1547-6898","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,7]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=itxc20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=itxc20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-01-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-20","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}